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Introduction: HER-2 is part of a highly interactive signaling network that may impair efficacy of endocrine
therapy. A sequential treatment design was chosen in this trial to ensure complete resistance to single agent
non-steroidal aromatase inhibitor (AI) and trastuzumab (T) both given as monotherapy before receiving both a
non-steroidal AI and T in combination. Clinical activity with combined treatment of AI and T after progression of
single agent treatments could indicate restoration of sensitivity as a consequence of cross-talk and networking
between both pathways.
Methods: Key eligibility criteria included postmenopausal patients with advanced, measurable, HER-2 positive
[assessed by FISH, ratio (≥2)], hormone receptor (HR) positive disease and progression on prior treatment with
a non-steroidal AI, e.g. letrozole or anastrozole, either in the adjuvant or advanced setting. Patients received
standard dose T monotherapy in step 1 and upon disease progression, continued T in combination with
letrozole in step 2. The primary endpoint was clinical benefit rate (CBR: CR, PR or DS ≥ 6 months) in step 2.
Results: Thirteen patients were enrolled. In step 1, six patients (46%) achieved CBR. Median time to
progression (TTP) was 161 days (95% confidence interval (CI): 82-281). CBR was observed in eight out of the
eleven evaluable patients (73%) in step 2, including one patient with partial response. Median TTP for all
eleven patients was 188 days (95% CI: 77-not reached). Mean time on trial treatment (TTP in step 1 plus TTP
in step 2) for patients reaching step 2 was 420 days (range: 174-990).
Conclusion: Results of this proof-of-concept trial suggest that complete resistance to both AI and T can be
overcome in a proportion of patients by combined treatment of AI and T, as all patients served as their own
control. Our results appear promising for a new treatment strategy which offers a chemotherapy-free option for
at least a subset of patients with ER positive, HER-2 positive breast cancer over a clinical relevant time period.
Abstract (updated)
We hypothesized that the clinical relevance of the upfront combined
inhibition of hormonal and growth factor pathways was undefined, and
a sequential approach might be advantageous. Thus a sequential
treatment design was chosen in this proof-of-concept-trial to ensure
complete clinical resistance to single agent therapy before receiving
both a non-steroidal AI and T. We speculated, that clinical anti-tumor
activity with combined treatment of AI and T after progression of single
agent treatments could indicate restoration of sensitivity as a
consequence of cross-talk between both pathways.
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Key eligibility criteria
• Histologically or cytologically confirmed diagnosis of breast cancer
• ER and/or PgR ≥ 10 fmol/mg cytosol protein; or 10% of the tumor
cells positive by immunohistochemical evaluation
• HER-2 amplification (≥ 2) by FISH
• Progression after prior treatment with a non-steroidal AI, e.g.
letrozole or anastrozole, either in an adjuvant or an advanced setting
Trial Overview Results Summary & Discussion
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Treatment Plan
Treatment in step 1 consisted of T monotherapy given as an initial
dose of 4 mg/kg iv followed by a weekly dose of 2 mg/kg iv or an initial
dose of 8 mg/kg iv followed by a dose of 6 mg/kg iv every 3 weeks (at
the discretion of the investigator) until tumor progression. After tumor
progression (same key exclusion criteria as at trial entry), T was
continued (at the same dose and schedule as in step 1) together with
letrozole 2.5 mg daily in patients eligible for step 2.
Sample size calculations deduced that twenty evaluable patients were
required for step 2. A CBR of at least 20% in step 2 would have been
considered clinically interesting.
Endpoints
Primary endpoint: CBR in step 2
Secondary endpoints: CBR in step 1, TTP, TTF, safety, duration of CB
Baseline Characteristics
Patient ER* (%) PgR (%) High 
level
HER-2†
Centromer ratio
≥ 6 or clustering
of HER-2 signal
Prior AI AI Use AI Duration 
(months)**
Metastatic sites
1 20 70 Yes Yes A Adjuvant 4 Bone
2 40 0 Yes Yes A Adjuvant 11 Bone, Lymph nodes
3 40 10 No No A Adjuvant 15 Bone, Lymph nodes, Lung, 
Liver
4 90 5 Yes Yes L Adjuvant 13 Bone
5 50 50 Yes Yes L Metastatic 13 Bone, Lung
6 90 75 No No L Metastatic 20 Bone, Lymph nodes, Liver, 
Other
7 90 10 No No L Metastatic 6 Lung, Pleura, Liver
8 99 5 Yes Yes A Metastatic 4 Bone, Primary tumor
9 75 69 Yes Yes L Metastatic 20 Bone, Lymph nodes
10 20 0 Yes Yes L Metastatic 3 Bone, Lymph nodes
11 70 30 Yes No A Adjuvant 36 Bone
12 Bio. pos Bio. Pos. No No A Metastatic 35 Lymph nodes, Lung
13 90 0 Yes Yes A Adjuvant 60 Lymph nodes, Lung
* ER quantitative, † High-level amplified HER-2 tumors: (FISH HER-2 signal : centromer ratio ≥ 4), ** prior to trial entry
AI: Aromatase Inhibitor; A: Anastrozole; L: Letrozole; Bio. Pos.: Biochemical positive
Summary of Main Efficacy Endpoints
Step No. of Patients with CB
n (%)
Duration of CB (days)
Median (95% CI)
TTP (days)
Median (95% CI)
TTF (days)
Median (95% CI)
Step 1 (N=13):
Trastuzumab
6 ( 46%) 267 (161 – 627) 161 (82 – 281) 98 (82 – 168)
Step 2 (N=11):
Trastuzumab + Letrozole 
8 ( 73%)
Primary endpoint
286 (161 – NC) 188 (77 – NC) 184 (77 – NC)
NC = not calculable; CI = Confidence Interval
Kaplan-Meier curves for TTP
This trial was closed early due to slow accrual. However the goal of
the trial – proof-of-concept for clinical relevant activity of combination
AI plus T in patients with resistant disease to single agent exposure -
was achieved with less patients accrued than initially planned (20
patients) due to the surprisingly high CBR in the 13 patients included.
Although the results of this trial must be interpreted with caution
because of the small number of patients, it is in concordance with a
CBR of 65%, observed in twenty-six patients with ER+/HER+ breast
cancers receiving first-line treatment with letrozole and T within a
randomized trial (1). Furthermore, this finding is in line with results of
the anastrozole plus T arm (CBR 43%) of the randomized TAnDEM
trial (2) and of another phase II trial using letrozole and T (CBR 52%)
as first or second-line therapy (3).
The results of this trial suggest that complete clinical resistance to
both AI and T can be overcome in a proportion of patients by
combined treatment, as all patients served as their own control. It also
indicates at least partial restoration of sensitivity following this
treatment sequence, possibly as a consequence of bidirectional cross-
talk and networking between the endocrine and the HER-2 signaling
pathways.
In summary, this proof-of-concept trial provides additional clinical
evidence for a dynamic interdependence of the ER and HER-2
pathways. It further indicates, that sequential (vertical) blockade of
these pathways is feasible without compromising the effectiveness of
a combined (horizontal) treatment of targeted therapeutics, thus
offering a chemotherapy-free option for at least a subset of patients
with ER+/HER-2+ breast cancer.
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